Epithelial Ovarian Cancer (EOC) is a leading cause of cancer-related deaths among women, mainly due to a lack of early detection and screening methods. Advanced immunoassay techniques, such as Luminex and proximity extension assay (PEA) technology, show promise in improving EOC detection by utilizing highly sensitive and specific multiplex panels to detect multiple combinations of biomarkers. However, these advanced immunoassay techniques have certain limitations, especially in validating the performance characteristics such as specificity, sensitivity, limit of detection (LOD), and dynamic range for each EOC biomarker within the panel. Implementing multiplexing in point-of-care (POC) biosensors can enhance EOC biomarker detection, with Surface Plasmon Resonance (SPR) being a versatile option among optical biosensors. There is no study on multiplex SPR biosensors specifically tailored for diagnosing EOC. Recent studies have shown promising results in the single detection of EOC biomarkers using SPR, with LOD for cancer antigen 125 (CA125) at 0.01 U/mL−1and human epididymis protein 4 (HE4) at 1pM. This study proposes a potential roadmap for scientists and engineers in academia and industry to develop a cost effective yet highly efficient SPR biosensor platform for detecting EOC.
上皮性卵巢癌（EOC）是女性癌症相关死亡的主要原因，这主要归因于缺乏早期检测和筛查手段。先进的免疫分析技术，如Luminex和邻近延伸分析（PEA）技术，通过利用高灵敏度、高特异性的多重检测组合来识别多种生物标志物的联合表达，为改善EOC检测提供了希望。然而，这些先进免疫分析技术存在一定局限性，特别是在验证检测组合内各EOC生物标志物的性能特征（如特异性、灵敏度、检测限和动态范围）方面。在即时检测（POC）生物传感器中实现多重检测可增强EOC生物标志物的检测能力，其中表面等离子体共振（SPR）技术是光学生物传感器中一种多功能的选择。目前尚未有针对EOC诊断专门设计的SPR多重生物传感器的研究。近期研究表明，利用SPR技术对EOC生物标志物进行单一检测已取得显著进展，其中癌症抗原125（CA125）的检测限达到0.01 U/mL，人附睾蛋白4（HE4）的检测限达到1pM。本研究为学术界和工业界的科学家与工程师提出了一条潜在的技术路线，旨在开发一种成本效益高且高效的SPR生物传感器平台，用于EOC的检测。
肿瘤(癌症)患者之家